Comparison Analysis of IPO of Biotech Companies: Case Study of Innovent Biologics and Genor Biopharma

This study investigates the IPO strategy models of Innovent Biologics and Genor Biopharma, two major Chinese biopharmaceutical companies. The two companies are also involved in the oncology and immune disease drugs and taking the 18A listing system of Hong Kong as capital entry point to support their R&D-centered businesses. Innovent Biologics pursued an independent set of research and development projects, which attracted a wide range of investors and provided a stable post-IPO growth. On the other hand, Genor Biopharma used a hybrid approach and focused on a specific group of investors; however, this caused its stock value to fluctuate. The findings of the study stress the roles of strategic planning, investor diversification, and innovation when it comes to biotech IPOs. The main takeaway is that maintaining an R&D pipeline and having a diversified investor base creates positive sentiment and strengthens the future market perspective, all of which are invaluable tips for considering future biotech companies' listings.